Alnylam shares spike after vutrisiran aces HELIOS-B trial in ATTR-cardiomyopathy, setting up regulatory filings.

Bayer licenses European rights to BridgeBio's acoramidis, putting some big pharma muscle behind the ATTR cardiomyopathy treatment.

See the latest Alnylam Pharmaceuticals Inc stock price (ALNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.